Xaciato is a prescription vaginal gel containing clindamycin phosphate at a 2% concentration. Its U.S. FDA label identifies a single-dose intravaginal product for bacterial vaginosis in female patients age 12 years and older. Unlike Clindesse, which comes as a prefilled cream applicator, Xaciato is supplied in a tube with a user-filled single-dose applicator. A pharmacy order must match that complete package identity, not merely the words 'clindamycin 2%.'
The branded product is not metronidazole vaginal gel, not topical acne clindamycin and not a generic version of another vaginal product. Even when both a cream and gel are designed for single administration, vehicle differences, package assembly and specific warning language remain meaningful. A legitimate pharmacy should deliver the labeled product with its current Instructions for Use and answer route-specific questions before the patient takes it home.
The most targeted comparison is Nuvessa versus Xaciato, where both products are vaginal gels but contain different antibiotics. The Clindesse access page focuses on a single-dose cream, while this Xaciato page addresses its own brand, tube and applicator. None of these pages is a guarantee of pharmacy inventory or a recommendation to self-diagnose BV.
The following matrix is designed specifically for Xaciato clindamycin phosphate vaginal gel 2% rather than for every product with a similar ingredient name. It separates the prescription's precise dosage form, route and product-status questions from merchandising language. The comparison does not suggest that another brand, route or concentration can be substituted without pharmacist and prescriber verification.
Pay particular attention to 8 g tube and user-filled single-dose applicator delivering 5 g: this feature determines whether a displayed medicine matches the actual clinical order. A misleading search result can confuse Clindesse cream or metronidazole vaginal gel with the intended Xaciato clindamycin phosphate vaginal gel 2%. Product equivalence, if applicable, depends on the FDA reference and state pharmacy rules, while treatment changes require clinical authorization.
| Product check | Xaciato 2% vaginal gel | Commonly confused product |
|---|---|---|
| Active ingredient | Clindamycin phosphate | Metronidazole is different |
| Dosage form | Vaginal gel 2% | Clindesse is 2% cream |
| Package | 8 g tube with user-filled applicator | Not a prefilled Clindesse applicator |
| Dose delivered | 5 g gel containing 100 mg clindamycin | Not the entire 8 g tube |
| Labeled population | Females 12 years of age and older with BV | Prescription after clinician evaluation |
| Barrier warning | Polyurethane condoms not recommended during and 7 days after | Do not copy Clindesse 5-day rule |
| Pharmacy | Exact brand and device; valid Rx | No ingredient-only substitution |
The FDA label describes an 8 g tube of clindamycin 2% vaginal gel and a single user-filled disposable applicator that delivers 5 g of gel containing 100 mg of clindamycin. These numbers have different meanings: the total tube contents are not the same as the labeled delivered amount. The dispenser should supply the device and instructions required for the prescribed single-use product.
This distinction matters for online package descriptions. A listing that merely says 'clindamycin gel 2%' without stating vaginal use and the Xaciato kit could refer to a different medicine. A patient should not substitute an acne product, ordinary cream or repackaged gel to recreate the prescribed system.
Xaciato labeling covers BV in female patients aged 12 years and older. Clinical assessment remains necessary because vaginal symptoms may be caused by candidiasis, sexually transmitted infections, irritation or other conditions. The ingredient name does not establish that any particular symptom or discharge calls for clindamycin treatment.
The BV condition overview explains how different approved antibiotics enter a clinician's discussion. The pharmacist's role is to dispense an appropriate prescription after that medical decision, not to decide the diagnosis based on what was searched online.
The current Xaciato label states that polyurethane condoms are not recommended during treatment and for seven days afterward because reliability may be affected; it identifies latex or polyisoprene condoms as alternatives in that context. This warning differs from instructions supplied with some cream formulations and should not be flattened into a generic rule for all clindamycin vaginal drugs.
The medication also carries warnings for Clostridioides difficile-associated diarrhea and hypersensitivity. Relevant history and unexpected symptoms must be discussed with a healthcare professional. A product's local route does not eliminate the need to review antibiotic safety considerations.
Both products contain clindamycin and are intended for single-dose vaginal use, but Clindesse is a bioadhesive cream supplied prefilled, whereas Xaciato is a gel supplied with a user-filled applicator. The difference affects package matching, instructions and contraception counseling. Regulatory substitution is not established by the common 2% figure alone.
A pharmacy may reasonably ask the prescriber to clarify which drug product is intended if the prescription lacks a brand or precise dosage form. The Nuvessa versus Clindesse comparison describes another one-dose option without making any of the three brands interchangeable.
Read back the complete item: Xaciato, clindamycin phosphate vaginal gel 2%, original 8 g tube and correct disposable applicator. Verify that the dispensing pharmacist has supplied the patient instructions and the package has not been damaged or altered. A prescription fulfillment service should not advertise an unknown generic as though it were the branded Xaciato kit.
For online orders, verify U.S. pharmacy licensing, clinician prescription requirements and access to pharmacy support. Confirm availability directly before relying on a quoted dispatch time; FDA approval and online listing do not establish present inventory.
If symptoms persist or recur after treatment, an assessment may be needed to distinguish recurrent BV from another diagnosis. Automatically repeating a single-dose product because the original tube was convenient can delay correct care. The clinician may need to review pregnancy-related circumstances, sexual health history and other medicines.
If payment or coverage is a concern, ask the pharmacist and prescriber about verified alternatives with their own appropriate prescriptions. A cheaper-looking multi-day cream or metronidazole gel should not be substituted without changing the clinical plan explicitly.
The prescription should identify Xaciato clindamycin phosphate vaginal gel 2% and the intended intravaginal route. Before ordering, compare the pharmacy's product description to the clinical order: 8 g tube and user-filled single-dose applicator delivering 5 g. A matching active ingredient without the correct strength, vehicle or packaging is not enough. If the product named by the clinician is not the one shown in the pharmacy system, request clarification before the transaction is finalized.
At pickup, ask the pharmacist to read back the complete product and explain the appropriate handling of original Xaciato tube and single-use applicator kit. The goal is a documented prescription match, not the appearance of a familiar word on a store search page. Problems with damaged packages, unclear directions or a different dosage form should be resolved before use, because a self-directed replacement can change the treatment being delivered.
The key comparison is with Clindesse cream or metronidazole vaginal gel, a distinction that should be made clinically rather than by retailer category. For a separate but related decision, consult buy clindamycin vaginal cream; it does not authorize substitution for the medicine discussed here.
A genuine U.S. online pharmacy should require legitimate prescription for BV in labeled patients, show a U.S. contact address, provide access to a state-licensed pharmacist and maintain the appropriate state board license. These checkpoints matter for Xaciato clindamycin phosphate vaginal gel 2%, which has a route-specific label and should not be supplied through a no-prescription shortcut. Comparing websites solely by advertised shipping or low prices is not a reliable product-verification method.
A local pharmacy provides an opportunity to review 8 g tube and user-filled single-dose applicator delivering 5 g and to ask about a genuine supplier, the prescribed package and counseling. Online fulfillment can also be legitimate, but it still requires licensed dispensing. Ask both types of pharmacy the same product-specific questions; neither a website listing nor a database label establishes that the item is available for immediate pickup or dispatch.
For this item, an especially important question is polyurethane condom warning and antibiotic-associated diarrhea; bring relevant history to the consultation before a brand or formulation change. For a separate but related decision, consult rosacea treatment alternatives; it does not authorize substitution for the medicine discussed here.
Insurance coverage and cash payment should be evaluated after the pharmacy identifies Xaciato clindamycin phosphate vaginal gel 2%. A plan can have different preferences for a specific brand, product form, quantity or approved alternative. Ask for an actual claim result or current cash-pay total, including any dispensing or delivery fees. An evergreen article cannot provide a defensible universal price, coupon or promise of savings for this item.
If the requested medicine cannot be supplied, the alternatives may include Clindesse cream or metronidazole vaginal gel, but the words 'alternative' and 'generic' have different meanings. The prescriber must decide when an entirely different treatment is clinically appropriate. The pharmacist can check regulatory equivalence only for the exact product and applicable laws; patients should not adjust dosage, route or treatment duration on their own.
The central packaging checkpoint remains original Xaciato tube and single-use applicator kit, because the correct commercial name is not enough if the delivered form differs. For a separate but related decision, consult metronidazole topical; it does not authorize substitution for the medicine discussed here.
Xaciato contains clindamycin phosphate vaginal gel at a 2% clindamycin concentration.
No. Nuvessa contains metronidazole 1.3%, while Xaciato contains clindamycin 2%.
The label describes an 8 g tube and a user-filled single-dose applicator delivering 5 g of gel.
No. Clindesse is a prefilled cream product; Xaciato has a different gel-and-applicator design.
FDA labeling includes female patients 12 years and older with BV, subject to appropriate clinician assessment.
The current label warns against polyurethane condoms during treatment and for seven days afterward; consult the full instructions.
No. BV requires appropriate evaluation; discharge can reflect other conditions.
No. It is a U.S. prescription antibacterial vaginal medicine.
No. Verify product-specific FDA approval, form, device and applicable substitution rules.
A prescriber and pharmacist can discuss an appropriate alternative rather than replacing it silently with a different product.